Xiaolu Tao
Shanghai Harbour Engineering Design & Research Institute(CN)
Publications by Year
Research Areas
Hepatocellular Carcinoma Treatment and Prognosis, Pharmacogenetics and Drug Metabolism, Cancer, Hypoxia, and Metabolism, Cancer Immunotherapy and Biomarkers, Liver Disease Diagnosis and Treatment
Most-Cited Works
- → A phase II, randomized, double‐blind, placebo‐controlled study evaluating the efficacy and safety of MDX‐1100, a fully human anti‐CXCL10 monoclonal antibody, in combination with methotrexate in patients with rheumatoid arthritis(2011)195 cited
- → Anti-IP-10 antibody (BMS-936557) for ulcerative colitis: a phase II randomised study(2013)189 cited
- → Batoclimab vs Placebo for Generalized Myasthenia Gravis(2024)35 cited
- → An improved LC–ESI–MS–MS method for simultaneous quantitation of rosiglitazone and N-desmethyl rosiglitazone in human plasma(2008)27 cited
- → Effects of a Fixed-Dose Co-Formulation of Daclatasvir, Asunaprevir, and Beclabuvir on the Pharmacokinetics of a Cocktail of Cytochrome P450 and Drug Transporter Substrates in Healthy Subjects(2017)25 cited
- → Use of a cocktail probe to assess potential drug interactions with cytochrome P450 after administration of belatacept, a costimulatory immunomodulator(2016)16 cited
- → A Randomized Trial in Healthy Subjects to Assess the Bioequivalence of an Atazanavir/Cobicistat Fixed-Dose Combination Tablet versus Administration as Separate Agents(2014)13 cited
- → ICH M12 Drug Interaction Studies: Summary of the Efforts to Achieve Global Convergence(2025)11 cited
- → A Randomized, Placebo-Controlled Trial of MDX-1100, an Anti-IP-10 Antibody, for Moderately to Severely Active Ulcerative Colitis(2010)10 cited
- → Toripalimab in combination with HBM4003, an anti-CTLA-4 heavy chain-only antibody, in advanced melanoma and other solid tumors: an open-label phase I trial(2024)8 cited